Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 4.4% – Time to Sell?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s share price traded down 4.4% during mid-day trading on Wednesday . The stock traded as low as $7.04 and last traded at $7.16. 4,653,415 shares traded hands during trading, a decline of 70% from the average session volume of 15,549,441 shares. The stock had previously closed at $7.49.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 target price on shares of Recursion Pharmaceuticals in a report on Wednesday, December 11th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $9.25.

Recursion Pharmaceuticals Price Performance

The company has a market cap of $2.81 billion, a price-to-earnings ratio of -4.71 and a beta of 0.85. The company’s 50 day moving average price is $6.90 and its 200 day moving average price is $7.02. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). The business had revenue of $26.08 million during the quarter, compared to analysts’ expectations of $12.62 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. Recursion Pharmaceuticals’s revenue for the quarter was up 147.6% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.43) EPS. Equities research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Insider Buying and Selling at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of the company’s stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $7.64, for a total value of $87,455.08. Following the sale, the director now owns 7,066,113 shares of the company’s stock, valued at approximately $53,985,103.32. This represents a 0.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Michael Secora sold 15,000 shares of Recursion Pharmaceuticals stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $7.66, for a total value of $114,900.00. Following the transaction, the chief financial officer now directly owns 1,499,631 shares of the company’s stock, valued at $11,487,173.46. This trade represents a 0.99 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 55,341 shares of company stock valued at $393,490. 15.75% of the stock is owned by company insiders.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the business. GAMMA Investing LLC grew its position in shares of Recursion Pharmaceuticals by 1,979.2% in the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock valued at $35,000 after purchasing an additional 4,948 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in Recursion Pharmaceuticals by 6.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,176,191 shares of the company’s stock valued at $7,751,000 after buying an additional 67,464 shares during the last quarter. Franklin Resources Inc. raised its holdings in shares of Recursion Pharmaceuticals by 58.9% in the third quarter. Franklin Resources Inc. now owns 18,963 shares of the company’s stock worth $127,000 after acquiring an additional 7,027 shares during the last quarter. Sanctuary Advisors LLC acquired a new position in shares of Recursion Pharmaceuticals in the third quarter worth $89,000. Finally, Geode Capital Management LLC boosted its stake in shares of Recursion Pharmaceuticals by 13.7% during the third quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company’s stock valued at $35,803,000 after acquiring an additional 656,003 shares during the last quarter. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.